Programmed cell death ligand 1 (PD-L1)
Showing 1 - 25 of >10,000
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
Lichen Planus Trial in Cairo (Skin Biopsy)
Not yet recruiting
- Lichen Planus
- Skin Biopsy
-
Cairo, EgyptCairo University
May 14, 2021
Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)
Recruiting
- Large B-cell Lymphoma
- 89Zr-atezolizumab PET-imaging
-
Groningen, NetherlandsUniversity Medical Center Groningen
Jul 15, 2022
Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)
Recruiting
- Urothelial Carcinoma
- Zilovertamab vedotin
-
Cleveland, Ohio
- +11 more
Jan 25, 2023
NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)
Active, not recruiting
- Non-small Cell Lung Cancer
- Pembrolizumab
- +2 more
-
Hefei, Anhui, China
- +16 more
Oct 14, 2022
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1
Not yet recruiting
- Non-Small Cell Lung Cancer
- Capsulized Fecal Microbiota Transplant
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Aug 12, 2021
Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal
Not yet recruiting
- Nasopharyngeal and Hypopharyngeal Carcinoma
- immunohistochemical
-
Sohag, EgyptSohag University Hospital
Oct 23, 2022
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Small-cell Lung Cancer, Neoadjuvant Therapy Trial in Shanghai (Atezolizumab, Carboplatin, Etoposide)
Not yet recruiting
- Small-cell Lung Cancer
- Neoadjuvant Therapy
- Atezolizumab
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Jan 4, 2021
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Germ Cell Tumor Trial in Milano (Durvalumab, Tremelimumab)
Terminated
- Germ Cell Tumor
-
Milano, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
May 12, 2021
Melanoma Trial (biological, drug, radiation)
Withdrawn
- Melanoma
- Avelumab
- +17 more
- (no location specified)
Mar 17, 2021
NSCLC Trial (biological, drug, radiation)
Withdrawn
- Non-small Cell Lung Cancer
- avelumab
- +21 more
- (no location specified)
Mar 17, 2021
Urothelial Carcinoma Trial (biological, drug, radiation)
Withdrawn
- Urothelial Carcinoma
- avelumab
- +19 more
- (no location specified)
Mar 17, 2021
Head and Neck Squamous Cell Carcinoma Trial (biological, drug, radiation)
Withdrawn
- Head and Neck Squamous Cell Carcinoma
- Avelumab
- +21 more
- (no location specified)
Mar 17, 2021
Tumor-Infiltrating Lymphocytes and Programmed Cell Death -
Recruiting
- Breast Cancer
- +2 more
- Observational Study
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022